Exact Mass: 336.98427180000004
Exact Mass Matches: 336.98427180000004
Found 68 metabolites which its exact mass value is equals to given mass value 336.98427180000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
tenoxicam
M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors
Tenoxicam
Tenoxicam is only found in individuals that have used or taken this drug. It is an antiinflammatory agent with analgesic and antipyretic properties, and is used to treat osteoarthritis and control acute pain.The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss. M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors
Fenquizone
C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D045283 - Natriuretic Agents > D004232 - Diuretics
Sudoxicam
4-(2,5-Dihydroxypyrrol-1-yl)-N-(1,3-thiazol-2-yl)benzenesulfonamide
2-Bromo-6,8-dihydroxy-7-propyl-9H-pyrrolo[2,1-b][1,3]benzoxazine-9-one
4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid
4-(2,3-dichlorophenyl)-5,7-dihydro-2-methyl-5-oxo-Furo[3,4-b]pyridine-3-carboxylic acid
C15H9Cl2NO4 (336.99086140000003)
HTS 01037
HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.
1,1-DIOXOBENZO[B]THIOPHEN-2-YLMETHYL N-SUCCIMIDYL CARBONATE
2,4-Dichloro-5-(1-piperidinylsulfonyl)benzoic acid
N-(4-acetylphenyl)-2-(2,4-dichlorophenoxy)acetamide
C16H13Cl2NO3 (337.02724480000006)
tetrasodium,2-(1,2-dicarboxylatoethylamino)butanedioate
(Ferrocenylmethyl)trimethylammonium Bromide
C14H20BrFeN (337.01284100000004)
4-{[3-(Trifluoromethyl)pyridin-2-yl]oxy}benzenesulfonyl chloride
5-(2-CHLORO-6-METHYLPYRIMIDIN-4-YL)-4-(4-CHLOROPHENYL)-4H-1,2,4-TRIAZOLE-3-THIOL
ethyl 3-bromo-7-(trifluoromethyl)imidazo[1,2-a]pyrimidine-6-carboxylate
C10H7BrF3N3O2 (336.96736980000003)
ETHYL 5-BROMO-3-(2-CARBOXY-VINYL)-1H-INDOLE-2-CARBOXYLATE
5-Bromo-3-methoxy-2-(pyridin-4-ylmethoxy)benzoic acid
3-[[1-(3,4-dichlorophenyl)ethylideneamino]oxymethyl]benzoic acid
C16H13Cl2NO3 (337.02724480000006)
BIS(TRICYCLOHEXYLPHOSPHINE)-3-PHENYL-1H-INDEN-1-YLIDENERUTHENIUM(II)DICHLORIDE
5-Bromo-N-(4-methoxybenzyl)-3-nitropyridin-2-amine
Neodymium acetate,Neodymium(III) acetate hydrate
C6H11NdO7 (336.95820660000004)
6-chloro-N-cyclopentyl-5-iodo-2-methylpyrimidin-4-amine
C10H13ClIN3 (336.98427180000004)
4-(4-BROMOPHENYLTHIO)-3-NITROBENZALDEHYDE
C13H8BrNO3S (336.9408238000001)
ethyl 2-(broMoMethyl)-8-cyano-7-MethoxyiMidazo[1,2-a]pyridine-3-carboxylate
1-(4-(5-Bromopyridin-2-yl)piperazin-1-yl)-2,2,2-trifluoroethanone
(5r)-3-(3-fluoro-4-iodophenyl)-5-hydroxymethyloxazolidin-2-one
C10H9FINO3 (336.96112059999996)
4-[(4-CHLORO-2,5-DIMETHYLPHENYL)THIO]-3-NITROBENZOIC ACID
5-(3-IODOPROPOXY)-2-NITROBENZYL ALCOHOL
C10H12INO4 (336.98110620000006)
Sudoxicam
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
Clodanolene
C14H9Cl2N3O3 (337.00209440000003)
C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant
5-[(6-Nitro-1,3-benzodioxol-5-yl)hydrazinylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
C11H7N5O6S (337.01170420000005)
[(2R,3S,4R,5R)-5-(4-carbamoyl-5-oxidoimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
fenquizone
C - Cardiovascular system > C03 - Diuretics > C03B - Low-ceiling diuretics, excl. thiazides > C03BA - Sulfonamides, plain C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D045283 - Natriuretic Agents > D004232 - Diuretics
4-carbamoyl-1-(5-O-phosphonato-beta-D-ribofuranosyl)-1H-imidazol-3-ium-5-olate
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D000970 - Antineoplastic Agents D018501 - Antirheumatic Agents D004791 - Enzyme Inhibitors
2-N,6-O-disulfo-alpha-D-glucosamine
C6H11NO11S2-2 (336.97735359999996)
(L-cysteinato-kappaS~3~)(methyl)mercury
C4H9HgNO2S (337.00602940000005)
2-N,3-O-disulfo-alpha-D-glucosamine
C6H11NO11S2-2 (336.97735359999996)
(E)-4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid
HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.
Disufenton
C11H15NO7S2 (337.02899199999996)
C26170 - Protective Agent > C1509 - Neuroprotective Agent D020011 - Protective Agents > D000975 - Antioxidants D002317 - Cardiovascular Agents
5-amino-1-(5-phosphonato-D-ribosyl)imidazolium-4-carboxylate(2-)
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-methyl-1,1,4-trioxo-N-(2-pyridinyl)-3H-thieno[2,3-e]thiazine-3-carboxamide
2-[(2,4-Dichlorophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole
2-N,6-O-disulfonato-D-glucosamine(2-)
C6H11NO11S2-2 (336.97735359999996)
2-[[5-(3-fluorophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-(1,3,4-thiadiazol-2-yl)acetamide
5-amino-1-(5-phosphonato-D-ribosyl)imidazolium-4-carboxylate(2-)
An organophosphate oxoanion that is the major structure at pH 7.3 of 5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxylic acid.